Negma Group has converted 230 convertible bonds in Oxurion resulting in a EUR 575,000 capital increase. This is part of Negma Group's EUR 30 million Capital Commitment1 that will allow Oxurion to focus
Nature article details how the NIH SAVE program helps inform COVID-19 pandemic policy worldwideNEW YORK, NY / ACCESSWIRE / April 26, 2022 / Dr. Anthony Fauci, Director of the National Institute of Allergy
Leuven, BELGIUM, Boston, MA, US - 11 April 2022 - 7.00 AM CET - Oxurion NV(Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a
Israeli-American Star Noa Tishby Returns as HostNEW YORK, NY / ACCESSWIRE / April 5, 2022 / Americans for Ben-Gurion University (A4BGU) announces its Celebrating the Remarkable 2 free virtual event will